 |
|
|
| |
Ex vivo identification of highly effective latency-reversing drug combinations
|
| |
| |
"Using multiple assays for latency reversal, we have completed the first ex vivo comparative study to identify highly effective LRA combinations. We demonstrated that select PKC agonist-containing combinations reverse latency at levels approaching those seen with maximal T cell activation."
Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
Gregory M. Laird1, C. Korin Bullen1, Daniel I.S. Rosenbloom2, Alyssa R. Martin3, Alison L. Hill4,
Christine M. Durand1, Janet D. Siliciano1, and Robert F. Siliciano1,5
These authors contributed equally to this work
1 Department of Medicine, Johns Hopkins University School of Medicine; 2 Department of Biomedical Informatics, Columbia University Medical Center;
3 Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine; 4 Program for Evolutionary Dynamics, Harvard University; 5 Howard Hughes Medical Institute
|
| |
|
|
|
|
|
